D9319C00001- 1L OC Mono Global RCT
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
366actual
Sites
89
Countries
Chile, China, Colombia +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-05-31 | actual | When the study began enrolling |
| Primary completion | 2026-07-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-07-27 | estimated | The whole study's end, after follow-up |
| First posted | 2021-05-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ovarian Cancer
Interventions
- Drug: Olaparib
- Other: Matching placebo
Primary outcomes
what the primary-completion date above is the date OFSuperiority of olaparib as maintenance treatment relative to placebo by assessment of PFS in participants with Stage III/IV ovarian cancer with a BRCAwt HRD positive tumour and a CR/PR following standard 1st line platinum based chemotherapy treatment.
measured Approximately 3 years
Superiority of olaparib as maintenance treatment relative to placebo by assessment of PFS in participants with Stage III/IV ovarian cancer with a BRCAwt tumour and a CR/PR following standard 1st line platinum-based chemotherapy treatment.
measured Approximately 3 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed